Tag: hepatitis C

Image: PD 1. A single-tablet regimen of ledipasvir and sofosbuvir produced high rates of sustained virologic response among patients with chronic hepatitis C virus genotype 1 infection who had previously failed conventional interferon therapy.  2. No patient discontinued therapy due to an adverse event.  Evidence Rating Level: 1 (Excellent)       Study...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection The current FDA-approved regimen for treatment of Hepatitis C (HCV) genotype 1...
Image: PD  1. From a cohort study of patients infected with hepatitis C virus (HCV), those with concurrent human immunodeficiency virus (HIV) infection had a slightly higher rate of hepatic decompensation, particularly those with a lower CD4 count and higher HIV viral load.  Evidence Rating Level: 2 (Good)  Study Rundown:  Concurrent HIV...
Image: PD  1. Combination therapy of HCV protease inhibitor ABT-450, nonnucleoside polymerase inhibitor ABT-333, and NS5A inhibitor ABT-267 achieved high, sustained virologic response rates.  2. The new regimen had a more favorable tolerance and safety profile compared to the current gold standard.  Evidence Rating Level: 1 (Excellent)        Study Rundown: Hepatitis...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Dolutegravir Plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection Antiretroviral therapy in the treatment of human immunodeficiency virus (HIV) infection has dramatically improved the survival of HIV-positive patients, but traditional...
Image: PD  1. Participants treated for 24 weeks with sofosbuvir and either weight-based or low-dose ribavirin achieved undetectable viral loads of 68% and 48% respectively.  2. Factors associated with relapse include male sex, advanced liver disease, and high baseline Hepatitis C virus RNA before treatment.  Evidence Rating Level: 1 (Excellent)    ...
Image: PD 1. Patients with hepatitis C genotype 1 treated with a combination of faldaprevir, deleobuvir and ribavirin achieved sustained virologic response rates up to 69%.  2. Patients with viral subtype 1b had higher response rates than patients with 1a.  Patients who possessed the IL28B genotype CC responded better than those...
May 13 – 19, 2013 In this section, we will highlight the some of the recent high-impact studies, updates, and analyses published in the past week. Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus Reminiscent of past SARS or H1N1 epidemics, a new rapidly progressing lower respiratory tract infection leading...
Image: PD 1. The addition of sofosbuvir to peginterferon-ribavirin was effective at achieving sustained virologic response against HCV genotypes 1, 4, 5 and 6. For HCV genotypes 2 and 3, sofosbuvir and ribavirin was non-inferior to current treatment (peginterferon-ribavirin).  2. Patients treated with sofosbuvir experienced fewer adverse events overall.  Evidence Rating Level:...